Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Virazole study

Executive Summary

ICN and its Viratek and SPI Pharmaceutical subsidiaries have signed a 15-year agreement with the U.S. Army Medical Research & Development Command for "cooperative study of the antiviral drug" ribavirin, according to a June 18 announcement. The Army has agreed to file "one or more NDAs for intravenous and oral" ribavirin within nine and 24 months, respectively.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel